Repurposing in a crisis: Tackling the COVID-19 wildfire

Reaction Biology is proudly sponsoring a webinar hosted by Drug Discovery News on COVID-19 about tackling the unique challenges of accelerating drug development by repurposing existing therapies where each day missed equals lives lost.

Topics covered:

• SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
• Identifying inhibitors of SARS-CoV-2 replication by profiling a library of known drugs.

To support the drug discovery community in the challenge to identify efficacious COVID-19 drugs, we have developed specific assays to block SARS-CoV-2 virus entry and replication, including: 

• Biophysical binding assays to block S protein and ACE2 interaction.
• Enzymatic inhibition assays for Furin,  PLpro and Cathepsin L proteases.
• Enzymatic inhibition assays for Mpro and TMPRSS2 proteases will be coming soon